Home » Newsletters » BioWorld Science

BioWorld Science

Nov. 28, 2011

View Archived Issues

GlaxoSmithKline reflects on achievements of third quarter 2011

In vitro and clinical data presented on Vitae Pharmaceuticals' renin inhibitor

Bristol-Myers Squibb offers report on third quarter 2011

Mibefradil dihydrochloride given with temozolomide in murine glioma model

Lilly initiates patient recruitment in phase III study of LY-2439821

Novartis obtains approval in Japan for new indication for Sandostatin LAR

Japanese authorities approve Beselna cream for actinic keratosis

Japanese researchers identify new biomarker for diagnosis/monitoring of RA

Angiogenesis inhibitor may enhance effects of therapy with oncolytic virus

Preclinical results reported for LEE-011 in human liposarcoma

Canadian and Chinese scientists disclose new flavonoid dimers

Novel compounds for diabetes prepared by Chinese team

biOasis enters agreement with Shire Human Genetic Therapies

Novel neuropeptide S receptor antagonists presented by U.S. team

Synairgen reports preclinical results of aerosolized IFN-beta use in viral pneumonia

Hanmi applies for E.U. orphan drug designation for LAPS-rhGH

New iron complexes for cancer disclosed by IHI Corporation

New nicotinic acetylcholine alpha7 receptor ligand prodrugs disclosed by Bristol-Myers Squibb

Bausch & Lomb completes patient recruitment in BOL-303259-X study

NIH discontinues use of tenofovir gel in HIV prevention study

European Commission approves Novartis' triple combination pill for high blood pressure

Japanese authorities expand approval of Pfizer's Diflucan

NICE recommends Eliquis for prevention of VTE in hip and knee surgery

Inspiration Biopharmaceuticals begins second pivotal study of OBI-1

Regeneron and Bayer commence Chinese phase III study of Eylea

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 30, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 30, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
Shionogi nabs revenue-generating ALS drugs with $2.5B Tanabe pact
BioWorld
Shionogi & Co. Ltd. will acquire global rights to U.S. FDA approved amyotrophic lateral sclerosis therapy edaravone through a $2.5 billion acquisition deal with...
Big pharma taps fast Asia innovation in search of next Keytruda
BioWorld
Speed and innovation from Asia Pacific’s (APAC) biotechnology sector had big pharma scouring the region for the next oncology heir to Keytruda (pembrolizumab),...